| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000022091 |
| Receipt No. | R000025472 |
| Scientific Title | The test of enhancing effects of metabolism and refreshed feeling by the combination of the amino acid mix ingestion and sauna bath. |
| Date of disclosure of the study information | 2016/04/27 |
| Last modified on | 2020/10/05 (Ver. 4) |
| Basic information | ||
| Public title | The test of enhancing effects of metabolism and refreshed feeling by the combination of the amino acid mix ingestion and sauna bath. | |
| Acronym | The effects test of the combination of the amino acid mix ingestion and sauna bath. | |
| Scientific Title | The test of enhancing effects of metabolism and refreshed feeling by the combination of the amino acid mix ingestion and sauna bath. | |
| Scientific Title:Acronym | The effects test of the combination of the amino acid mix ingestion and sauna bath. | |
| Region |
|
|
| Condition | |||
| Condition | Healthy adult | ||
| Classification by specialty |
|
||
| Classification by malignancy | Others | ||
| Genomic information | NO | ||
| Objectives | |
| Narrative objectives1 | To evaluate the effects which influence to metabolism and refreshed feeling in sauna bath by single ingestion of amino acid mixture. |
| Basic objectives2 | Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | Physiological index and refreshing feeling,on the day of the single ingestion.
*Blood flow of skin surface *Amount of sweat *Body surface temperature *Visual analog scale |
| Key secondary outcomes | Physiological index,on the day of the single ingestion.
*Tympanic temperature *Acceleration pulse wave Blood test,on the day of the single ingestion. *Metabolite of nitric oxide *Cortisol *Free fatty acid Cognitive function test, on the day of the single ingestion. |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Cross-over |
| Randomization | Randomized |
| Randomization unit | Individual |
| Blinding | Double blind -all involved are blinded |
| Control | Placebo |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 2 | |
| Purpose of intervention | Prevention | |
| Type of intervention |
|
|
| Interventions/Control_1 | Amino acid mixture, single ingestion - Wash out 1 week - Placebo, single ingestion | |
| Interventions/Control_2 | Placebo, single ingestion - Wash out 1 week - Amino acid mixture, single ingestion
|
|
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male | |||
| Key inclusion criteria | 1) Subjects who can make self-judgment and are voluntarily giving written informed consent.
2) Subject who can use personal sauna bath without unreasonable. 3) Healthy males aged 20 to 49 years old, who meet the followings at the day of screening test. (1) Subjects who regarded as appropriate by the doctor from the results of screening test. (2) Healthy males who have BMI value between 18.5 and 25.0. (3) Health males who can conduct the cognitive function test. |
|||
| Key exclusion criteria | 1) Subjects who have previous and/or current medical history of malignant tumor, heart failure, myocardial infarction.
2) Subjects who have chronic disease and who are given continuous treatment by taking medicines. 3) Subjects who took drugs, quasi drugs, or supplements those concern about influence to the test results on daily basis within 3 month before screening test. Or, subjects who plan to take those drugs, quasi drugs, or supplements during test period. 4) Subjects who have previous medical history of drug and/or food allergy. 5) Subjects who difficult to sweat in sauna bath. 6) Subjects who excessive alcohol intake. (intake over 60g alcohol per day) 7) Subjects who have tattoo. 8) Subjects who have wide barns scar. 9) Subjects who removing hair. 10) Subjects who participated within 3-month prior to the current study and/or who plan to participate the other clinical tests. 11) Others who have been determined ineligible by principal investigator or sub-investigator. |
|||
| Target sample size | 10 | |||
| Research contact person | |||||||
| Name of lead principal investigator |
|
||||||
| Organization | CPCC Company Limited | ||||||
| Division name | Clinical Research Planning Department | ||||||
| Zip code | 101-0047 | ||||||
| Address | 4F Chusin Building, 3-3-5 Uchikanda Chiyoda-ku, Tokyo 101-0047, JAPAN | ||||||
| TEL | 03-5297-3112 | ||||||
| cpcc-contact@cpcc.co.jp | |||||||
| Public contact | |||||||
| Name of contact person |
|
||||||
| Organization | CPCC Company Limited | ||||||
| Division name | Plan Sales Department | ||||||
| Zip code | 101-0047 | ||||||
| Address | 4F Chusin Building, 3-3-5 Uchikanda Chiyoda-ku, Tokyo 101-0047, JAPAN | ||||||
| TEL | 03-5297-3112 | ||||||
| Homepage URL | |||||||
| cpcc-contact@cpcc.co.jp | |||||||
| Sponsor | |
| Institute | CPCC Company Limited |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Meiji Co., Ltd. |
| Organization | |
| Division | |
| Category of Funding Organization | Profit organization |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| IRB Contact (For public release) | |
| Organization | Institutional Review Board of Chiyoda Paramedical Care Clinic |
| Address | 2F Chushin Building, 3-3-5 Uchikanda Chiyoda-ku, Tokyo 101-0047, Japan |
| Tel | 03-5297-5548 |
| IRB@cpcc.co.jp | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| Result | |
| URL related to results and publications | |
| Number of participants that the trial has enrolled | |
| Results | |
| Results date posted | |
| Results Delayed | |
| Results Delay Reason | |
| Date of the first journal publication of results | |
| Baseline Characteristics | |
| Participant flow | |
| Adverse events | |
| Outcome measures | |
| Plan to share IPD | |
| IPD sharing Plan description | |
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Date of IRB | |||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date | |||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Other | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000025472 |